The issue of lymphadenectomy during laparoscopic gastrectomy for gastric carcinoma

Muhammed Ashraf Memon, Nick Butler, Breda Memon

Muhammed Ashraf Memon, Nick Butler, Breda Memon, Department of Surgery, Ipswich Hospital, Chelmsford Avenue, Ipswich, Queensland 4305, Australia
Muhammed Ashraf Memon, Department of Surgery, University of Queensland, Mayne Medical School, Herston Road, Herston, Queensland 4006, Australia; Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Queensland 4229, Australia; Faculty of Health Sciences, Bolton University, Deane Road, Bolton, Lancashire BL3 5AB, United Kingdom

Author contributions: All authors were involved in drafting the manuscript and revising it critically for important intellectual content. Furthermore, all authors have participated sufficiently in the work to take public responsibility for its content.

Correspondence to: Muhammed Ashraf Memon, FRCS, FRACS, Professor, Department of Surgery, Ipswich Hospital, Chelmsford Avenue, Ipswich, Queensland 4305, Australia. mmemon@yahoo.com
Telephone: +61-448614170 Fax: +61-7-38101592
Received: March 16, 2009 Revised: July 25, 2009
Accepted: August 1, 2009
Published online: February 15, 2010

Abstract

Surgical resection remains the mainstay of treatment for gastric cancer. Laparoscopic assisted gastrectomy has failed to gain universal acceptance as an alternative to the open approach for a number of reasons, one of which includes the issue of oncological radicality in terms of lymph node dissection. Nodal status, which is one of the most crucial and independent predictors of patient survival, therefore has been examined both in single institutional trials and also in randomised controlled trials especially on early gastric cancer. The issue of oncological adequacy for laparoscopic lymph node harvesting for advanced gastric cancer remains a contentious issue because of the unique challenges it poses in terms of complexity, safety and time, and also the lack of randomised controlled trials in this area. It is thus imperative that good quality multicentre randomised controlled trials are designed to investigate the benefits of extended lymphadenectomy in the setting of laparoscopic surgery, especially for advanced gastric cancer and its impact on both short and long term survival.

© 2010 Baishideng. All rights reserved.

Key words: Gastrectomy; Meta-analysis; Randomised controlled trials; Laparoscopic method; Comparative studies; Retrospective trials; Lympadenectomy; Patient’s outcome

Peer reviewer: Gregory Kouraklis, Associate Professor, Medical School, University of Athens, 122 Vasillis Sohas Avenue, Athens 11526, Greece

Memon MA, Butler N, Memon B. The issue of lymphadenectomy during laparoscopic gastrectomy for gastric carcinoma. World J Gastrointest Oncol 2010; 2(2): 65-67 Available from: URL: http://www.wjgnet.com/1948-5204/full/v2/i2/65.htm DOI: http://dx.doi.org/10.4251/wjgo.v2.i2.65

Minimal access gastrointestinal surgery for gastric cancer; i.e. laparoscopic distal gastrectomy (LDG), has not achieved universal acceptance by the surgical fraternity although introduced 13 years ago. The reasons are both technical and oncological. Recently, however, there has been a tremendous amount of advancement in the development of laparoscopic instruments which, coupled with increasing experience in the performance of complex laparoscopic gastrointestinal procedures, have led to the expansion of minimal access surgery for both benign and malignant gastric procedures. The following editorial will discuss some of these contentious issues and progress made in this area.

Laparoscopic assisted gastrectomy (LAG) for the management of gastric malignancy is becoming increasingly popular. It was introduced 13 years ago by a group of Japanese surgeons[1]. Its wider acceptance, however, as an alternative to the open approach remains a contentious subject, especially because of the technical difficulties involved in achieving an adequate lymph node dissection,
an issue that is viewed differently by Eastern and Western surgeons. Various trials have estimated that there will be lymph node involvement in 3%-5% of gastric cancer cases limited to mucosa only, 11%-25% lymph node involvement if the cancer involves submucosa, 50% lymph node involvement in T2 cancer and 83% lymph node involvement in T3 cancer. Nodal status, thus, is one of the most crucial and independent predictors of patient survival. Therefore, the issue of oncology radicality for lymph node harvesting, especially for both early and advanced gastric cancer during LAG, remains hotly debated because of the unique challenge it poses in terms of complexity, safety and time. Many gastrointestinal surgeons, at least in the West, consider laparoscopic D2 lymph node dissection to be tedious, onerous, unnecessary and even unsafe. This assumption is based on a number of randomised controlled trials (level I evidence) comparing open D1 vs D2 lymphadenectomy for gastric cancer, which has shown no long term survival advantage and a higher perioperative complication rate and death in the D2 group. Furthermore, the cochrane Review has confirmed these findings. However, many groups, especially from the East, differ on this issue based on their large retrospective data showing significant benefits and modest morbidity from extended lymph node dissection. Some of the groups with extensive open D2 experience have since consolidated their experience with LAG and have now published randomised controlled trials (RCTs) comparing LDG and open distal gastrectomy (ODG). The RCTs have examined the issue of laparoscopic radicality of lymph node dissection mainly in early gastric cancer. To date, all the RCTs (level I evidence) have found lymph node retrieval during a laparoscopic procedure to be not only sufficient but meeting the global standard for adequate staging, emphasizing the oncological radicality of laparoscopic gastric procedures. In fact, in none of the RCTs was there any significant statistical difference in lymph node retrieval for the two procedures. However, a recent meta-analysis, which pooled together the results of four RCTs, has come to a different conclusion altogether. The authors of this meta-analysis have shown that there was a statistically significant reduction in lymph node harvesting for LDG compared to ODG, which may translate into an overall survival disadvantage for patients having LDG. As the long term results for the majority of these trials have not been published, this assumption is difficult to corroborate. However, the long term results are eagerly awaited.

The argument on the merits and risks of extended lymph node clearance for AGC during LAG is additionally controversial because of the absence of level I or II evidence. Hwang et al reported their experience of LAG for AGC. They compared LAG (n = 45) with ODG (n = 83) performed between 2004 and 2007 in a non-randomized fashion. These authors found no difference in the mean number of nodes harvested in either group and felt that extended lymphadenectomy for AGC is possible and safe. Furthermore, the authors felt that there was good evidence that LAG was superior in improving the quality of life. However, the mean follow-up of the patients was around two years and therefore long term results in terms of disease free survival and mortality are not known. Similarly, Kawamura et al in yet another non-randomized trial comparing LDG (n = 53) and ODG (n = 67) over a two year period examined the safety and accuracy of D2 dissection for AGC. They concluded that D2 dissection could be performed safely and accurately without undue complications provided the surgical team was skilled in minimally invasive surgical techniques. However, they conceded that no long term results for LDG for AGC are available and therefore the need for an RCT is important to address this issue.

Zhang et al looked at 10 years of experience in their unit with 391 laparoscopic gastrectomies from 1998 to 2007. In 100 patients (25.6%), the number of lymph nodes retrieved was less than 15. This number is less than one would expect even for D1 lymphadenectomy suggesting that the extent of lymphadenectomy achieved by these authors in a quarter of their patients did not approach the global standard for accurate staging. The findings of this trial suggest that even in experienced hands and in large volume centres, extended lymphadenectomy poses a challenge.

Nodal status, whether in LDG or ODG, remains the most important independent predictor of gastric cancer patient survival. The RCTs comparing LDG versus ODG for early gastric cancer have shown that the extent of lymphadenectomy achieved by current laparoscopic procedures approaches the global standard for accurate staging. Performing extended resection laparoscopically as recommended in Japan remains a challenge and is a time consuming process as evident from the Zhang et al study. Therefore, laparoscopic gastrectomy for AGC may only be justified under the setting of clinical trials in a high volume centre and in the hands of experienced laparoscopic gastric surgeons. Given the vast difference between Eastern and Western surgeons in surgical experience in gastric cancer surgery, and the difference in the prevalence of gastric cancer between the East and West and a higher rate of complications associated with a more aggressive resection, it is imperative that surgeons in the East take the lead in organising a good quality multicentre randomised controlled trial enrolling a large number of patients to address the issue of LDG versus ODG for the treatment of gastric cancer, with a main emphasis on extended lymph node resection and its impact on both short and long term survival.

REFERENCES

1 Kitano S, Iso Y, Moriyama M, Sugimachi K. Laparoscopy-assisted Billroth I gastrectomy. Surg Laparosc Endosc 1994; 4: 146-148
2 Oñate-Ocaña LF, Aiello-Crocifoglio V, Mondragón-Sánchez R, Ruiz-Molina JM. Survival benefit of D2 lymphadenectomy in patients with gastric adenocarcinoma. Ann Surg Oncol 2000; 7: 210-217
3 de Gara CJ, Hanson J, Hamilton S. A population-based study of tumor-node relationship, resection margins, and surgeon volume on gastric cancer survival. Am J Surg 2003,
Results of extended lymph node dissection for gastric cancer cases with N2 lymph node metastasis. *Int Surg* 1997; 82: 257-261

Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. *Ann Surg* 1998; 228: 449-461

Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. *J Clin Oncol* 2004; 22: 2069-2077

Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. *Br J Cancer* 1999; 79: 1522-1530

Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. *Cochrane Database Syst Rev* 2004; CD001964

A randomized controlled trial comparing open vs laparoscopic distal gastrectomy for the treatment of early gastric cancer: an interim report. *Surgery* 2002; 131: S306-S311

Lymphadenectomy and laparoscopic gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. *Ann Surg* 2005; 241: 232-237

A prospective randomized study comparing open vs laparoscopy-assisted distal gastrectomy in early gastric cancer: early results. *Surg Endosc* 2005; 19: 168-173

Prospective randomized study of open versus laparoscopy-assisted distal gastrectomy with extraperigastric lymph node dissection for early gastric cancer. *Surg Endosc* 2005; 19: 1172-1176

Current status of minimal access surgery for gastric cancer. *Surg Oncol* 2007; 16: 95-98

Analysis of laparoscopic and open distal gastrectomy for gastric carcinoma. *Surg Endosc* 2008; 22: 1781-1789

Laparoscopic-assisted distal gastrectomy versus open distal gastrectomy for advanced gastric cancer. *Surg Endosc* 2009; 23: 1252-1258

Inspection of safety and accuracy of D2 lymph node dissection in laparoscopy-assisted distal gastrectomy. *World J Surg* 2008; 32: 2366-2370

Curability of laparoscopic gastrectomy for gastric cancer: an analysis of 10 years' experience. *Gastric Cancer* 2008; 11: 175-180